• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

局部晚期头颈部癌患者的循环肿瘤细胞:其在预测非手术治疗反应和生存方面可能作用的初步报告。

Circulating tumour cells in locally advanced head and neck cancer: preliminary report about their possible role in predicting response to non-surgical treatment and survival.

机构信息

Radiation Oncology Department, Brescia University, Italy.

出版信息

Eur J Cancer. 2012 Nov;48(16):3019-26. doi: 10.1016/j.ejca.2012.05.007. Epub 2012 Jun 7.

DOI:10.1016/j.ejca.2012.05.007
PMID:22682019
Abstract

BACKGROUND AND PURPOSE

The mechanism of dissemination of locally advanced head and neck cancer (LAHNC) is far to be resolved. Circulating tumour cells (CTC) have been identified as a prognostic factor in metastatic breast and prostate cancer. This prospective multi-centric analysis studied the possible role of CTC identification in LAHNC.

MATERIALS AND METHODS

CTC were searched in 73 patients with LAHNC (oropharynx, n=39; nasopharynx, n=10; larynx, n=10; paranasal sinuses, n=6, of whom 3 with sinonasal undifferentiated carcinoma, SNUC; hypopharynx, n=5; oral cavity, n=3). All of them (apart from SNUC) had squamous cell cancers. The relationship between CTC positivity and other clinical prognostic factors has been investigated. Response to treatment and survival has been related with changes in CTC number during the treatment.

RESULTS

CTC were frequently identified in oro- and hypopharyngeal cancer and in SNUC. They were more frequent in stage IV than in stages I-III disease (18% versus 6%, p=NS (not significant)). Partial or complete response (CR) was related with the absence or disappearance of CTC during treatment (p=0.017). A decrease in the CTC number or their absence throughout the treatment seems also related with non-progressive disease, after both complete or incomplete remission and with the proportion of patients alive and NED (no evidence of disease) (p=0.009).

CONCLUSIONS

These preliminary data suggest a possible role of CTC determination in head and neck cancer. Additional and longer follow up data need to be collected to confirm these findings.

摘要

背景与目的

局部晚期头颈部癌症(LAHNC)的播散机制尚未完全阐明。循环肿瘤细胞(CTC)已被确定为转移性乳腺癌和前列腺癌的预后因素。本前瞻性多中心分析研究了在 LAHNC 中鉴定 CTC 的可能作用。

材料与方法

在 73 例 LAHNC 患者(口咽癌,n=39;鼻咽癌,n=10;喉癌,n=10;副鼻窦癌,n=6,其中 3 例为未分化癌,SNUC;下咽癌,n=5;口腔癌,n=3)中搜索 CTC。除 SNUC 外,所有患者均为鳞状细胞癌。研究了 CTC 阳性与其他临床预后因素之间的关系。治疗反应和生存与治疗过程中 CTC 数量的变化有关。

结果

在口咽癌和下咽癌以及 SNUC 中经常发现 CTC。IV 期患者的 CTC 阳性率高于 I-III 期患者(18%比 6%,p=NS(无统计学意义))。部分或完全缓解(CR)与治疗期间 CTC 缺失或消失有关(p=0.017)。治疗过程中 CTC 数量减少或消失似乎也与非进行性疾病有关,无论是完全缓解还是不完全缓解后,与存活且无疾病证据(NED)的患者比例有关(p=0.009)。

结论

这些初步数据提示 CTC 测定在头颈部癌症中可能具有一定作用。需要收集更多和更长的随访数据来证实这些发现。

相似文献

1
Circulating tumour cells in locally advanced head and neck cancer: preliminary report about their possible role in predicting response to non-surgical treatment and survival.局部晚期头颈部癌患者的循环肿瘤细胞:其在预测非手术治疗反应和生存方面可能作用的初步报告。
Eur J Cancer. 2012 Nov;48(16):3019-26. doi: 10.1016/j.ejca.2012.05.007. Epub 2012 Jun 7.
2
Cetuximab plus radiotherapy in patients with unresectable locally advanced squamous cell carcinoma of head and neck region--a open labelled single arm phase II study.西妥昔单抗联合放疗用于不可切除的局部晚期头颈部鳞状细胞癌患者——一项开放标签单臂II期研究。
Indian J Cancer. 2011 Apr-Jun;48(2):154-7. doi: 10.4103/0019-509X.82873.
3
Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.强化放化疗作为晚期头颈癌患者器官保留的主要治疗方法:疗效、毒性作用及局限性
Arch Otolaryngol Head Neck Surg. 2004 Jul;130(7):861-7. doi: 10.1001/archotol.130.7.861.
4
Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.局部晚期头颈癌患者综合治疗中的颈清扫术
Head Neck. 2004 May;26(5):447-55. doi: 10.1002/hed.10394.
5
Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.日本术后高危型头颈部鳞状细胞癌患者接受每周三次顺铂辅助放化疗的 II 期可行性试验。
Jpn J Clin Oncol. 2012 Oct;42(10):927-33. doi: 10.1093/jjco/hys128. Epub 2012 Aug 23.
6
c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.c-erbB-2癌蛋白在头颈部血管生成不良的鳞状细胞癌中过度表达,但与细胞毒性治疗反应或生存率无关。
Anticancer Res. 2000 Mar-Apr;20(2A):997-1004.
7
Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience.顺铂、氟尿嘧啶和左亚叶酸钙诱导化疗用于局部晚期头颈癌:MD安德森癌症中心的经验
Cancer J Sci Am. 1997 Mar-Apr;3(2):92-9.
8
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.一项III期研究,比较顺铂联合氟尿嘧啶与紫杉醇、顺铂和氟尿嘧啶诱导化疗,随后进行同步放化疗用于局部晚期头颈癌的疗效。
J Clin Oncol. 2005 Dec 1;23(34):8636-45. doi: 10.1200/JCO.2004.00.1990. Epub 2005 Nov 7.
9
A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.一项关于紫杉醇联合顺铂作为头颈部癌一线治疗的I/II期研究:初步结果。
Semin Oncol. 1995 Dec;22(6 Suppl 15):50-4.
10
Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.多西他赛每周一次同步给药联合同期推量放疗治疗局部晚期头颈部鳞状细胞癌
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1036-44. doi: 10.1016/j.ijrobp.2006.02.010. Epub 2006 May 6.

引用本文的文献

1
Potential role of circulating tumor cells and cell-free DNA as biomarkers in oral squamous cell carcinoma: A prospective single-center study.循环肿瘤细胞和游离DNA作为口腔鳞状细胞癌生物标志物的潜在作用:一项前瞻性单中心研究。
PLoS One. 2024 Dec 27;19(12):e0309178. doi: 10.1371/journal.pone.0309178. eCollection 2024.
2
Application of CellSearch technique in detection of peripheral blood circulating tumour cell count in patients with head and neck cancer and its association with prognosis.CellSearch技术在头颈部癌患者外周血循环肿瘤细胞计数检测中的应用及其与预后的关系。
Oncol Lett. 2024 Dec 13;29(2):100. doi: 10.3892/ol.2024.14846. eCollection 2025 Feb.
3
The Role of ctDNA and Liquid Biopsy in the Diagnosis and Monitoring of Head and Neck Cancer: Towards Precision Medicine.
循环肿瘤DNA(ctDNA)与液体活检在头颈部癌诊断和监测中的作用:迈向精准医学
Cancers (Basel). 2024 Sep 11;16(18):3129. doi: 10.3390/cancers16183129.
4
Particle Beam Radiobiology Status and Challenges: A PTCOG Radiobiology Subcommittee Report.粒子束放射生物学现状与挑战:国际粒子治疗协作组放射生物学小组委员会报告
Int J Part Ther. 2024 Aug 8;13:100626. doi: 10.1016/j.ijpt.2024.100626. eCollection 2024 Sep.
5
A FACS-based novel isolation technique identifies heterogeneous CTCs in oral squamous cell carcinoma.一种基于荧光激活细胞分选术的新型分离技术可识别口腔鳞状细胞癌中异质性循环肿瘤细胞。
Front Oncol. 2024 Feb 26;14:1269211. doi: 10.3389/fonc.2024.1269211. eCollection 2024.
6
Liquid Biopsy in Head and Neck Cancer: Its Present State and Future Role in Africa.头颈部癌症的液体活检:在非洲的现状和未来作用。
Cells. 2023 Nov 20;12(22):2663. doi: 10.3390/cells12222663.
7
Circulating tumor cell abundance in head and neck squamous cell carcinoma decreases with successful chemoradiation and cetuximab treatment.头颈部鳞状细胞癌中循环肿瘤细胞的丰度随着放化疗和西妥昔单抗治疗的成功而降低。
Cancer Lett. 2023 May 28;562:216187. doi: 10.1016/j.canlet.2023.216187. Epub 2023 Apr 15.
8
The Impact of Surgery on Circulating Malignant Tumour Cells in Oral Squamous Cell Carcinoma.手术对口腔鳞状细胞癌循环恶性肿瘤细胞的影响
Cancers (Basel). 2023 Jan 18;15(3):584. doi: 10.3390/cancers15030584.
9
Liquid Biopsy in Head and Neck Cancer: Current Evidence and Future Perspective on Squamous Cell, Salivary Gland, Paranasal Sinus and Nasopharyngeal Cancers.头颈部癌的液体活检:关于鳞状细胞癌、唾液腺癌、鼻窦癌和鼻咽癌的当前证据及未来展望
Cancers (Basel). 2022 Jun 9;14(12):2858. doi: 10.3390/cancers14122858.
10
Application of circulating tumour cells to predict response to treatment in head and neck cancer.循环肿瘤细胞在预测头颈部癌症治疗反应中的应用。
Cell Oncol (Dordr). 2022 Aug;45(4):543-555. doi: 10.1007/s13402-022-00681-w. Epub 2022 Jun 23.